BMJ Open (Apr 2022)

Concurrent chemoradiation and brachytherapy alone or in combination with nelfinavir in locally advanced cervical cancer (NELCER): study protocol for a phase III trial

  • Sudeep Gupta,
  • Reena Engineer,
  • Supriya Chopra,
  • Seema Gulia,
  • Jaya Ghosh,
  • Sadhna Kannan,
  • Santosh Menon,
  • Palak Popat,
  • Venkatesh Rangarajan,
  • Umesh Mahantshetty,
  • Kedar Deodhar,
  • Sushmita Rath,
  • Manjunath Nookala Krishnamurthy,
  • Prachi Mittal,
  • Jayant Sastri Goda,
  • Jaahid Mulani,
  • Sidharth Pant,
  • Venkatesh Pai,
  • Mayuri Charnalia,
  • Sneha Shah,
  • Vikram Gota,
  • Lavanya Naidu,
  • Sheela Sawant,
  • Praffula Thakkar

DOI
https://doi.org/10.1136/bmjopen-2021-055765
Journal volume & issue
Vol. 12, no. 4

Abstract

Read online

Introduction In locally advanced cervical cancer, nodal, local and distant relapse continue to be significant patterns of relapse. Therefore, strategies to improve the efficacy of chemoradiation are desirable such as biological pathway modifiers and immunomodulating agents. This trial will investigate the impact of nelfinavir, a protease inhibitor that targets the protein kinase B (AKT) pathway on disease-free survival (DFS).Methods and analysis Radiosensitising effect of nelfinavir in locally advanced carcinoma of cervix is a single-centre, open-label, parallel-group, 1:1 randomised phase-III study. Patients aged over 18 years with a diagnosis of carcinoma cervix stage III are eligible for the study. After consenting, patients will undergo randomisation to chemoradiation and brachytherapy arm or nelfinavir with chemoradiation and brachytherapy arm. The primary aim of the study is to compare the difference in 3-year DFS between the two arms. Secondary aims are locoregional control, overall survival, toxicity and quality of life between the two arms. Pharmacokinetics of nelfinavir and its impact on tumour AKT, programmed cell death ligand 1, cluster of differentiation 4, cluster of differentiation 8 and natural killer 1.1 expression will be investigated. The overall sample size of 348 with 1 planned interim analysis achieves 80% power at a 0.05 significance level to detect a HR of 0.66 when the proportion surviving in the control arm is 0.65. The planned study duration is 8 years.Ethics and dissemination The trial is approved by the Institutional Ethics Committee-I of Tata Memorial Hospital, Mumbai (reference number: IEC/0317/1543/001) and will be monitored by the data safety monitoring committee. The study results will be disseminated via peer-reviewed scientific journals, and conference presentations. Study participants will be accrued after obtaining written informed consent from them. The confidentiality and privacy of study participants will be maintained.Trial registration number The trial is registered with Clinical Trials Registry-India (CTRI/2017/08/009265) and ClinicalTrials.gov (NCT03256916).